Ajooni Biotech expects additional revenue of Rs 200 crore from commercial production of Moringa by FY 25-26

New Delhi:  Animal healthcare solutions provider Ajooni Biotech is expecting additional annual revenue of Rs 200 crore from commercial production of moringa by financial year 2025-26.

The leading animal feed manufacturer on Monday revealed its plans for commercial production of Moringa by financial year 2025-26.

“We anticipate generating significant additional annual revenue of Rs 15 crore to Rs 200 crore from our moringa operations with an estimated profit margin of 40-50 per cent by FY2026,” he said.

Moringa provides important benefits for animal welfare and Moringa oil, obtained from the seeds, displays promising characteristics for use in aviateo biofuels.

Recognizing this potential, Ajooni Biotech is actively integrating Moringa into its product development strategy, the statement said.Jasjot Singh, Managing Director, Ajooni Biotech, said, “The Moringa revolution is upon us, and Ajooni Biotech is at the forefront. Moringa, often called the ‘miracle tree’, holds immense potential for the future of animal health and sustainable practices. ”

Meanwhile, Ajooni Biotech aims to raise Rs 43.81 crore from the ongoing rights-issue, which opened on May 21 and will close on May 31.

Shareholders have the opportunity to acquire additional shares at a discounted price of Rs 5 per share – a discount of more than 20 per cent on the closing share price on March 18, 2024.

The funds raised through the rights issue will be helpful in moving towards our goal of starting commercial production of Moringa by FY 2026, Singh said.Singh said, “This focus positions Ajooni Biotech to capture a significant share of the market for natural and sustainable animal health care solutions. We have leased 64,000 square yards of land in Derabassi, Punjab for moring nursery and plantation. Have taken.”

The company said Ajooni Biotech’s rights issue marks a strategic step towards unlocking the huge potential of Moringa in the animal healthcare market, creating a sustainable and profitable future for Ajooni and its stakeholders.

Looking to the future, Ajooni Biotech has partnered with Unnati Agri-Allied and Marketin Multi State Cooperative Society Limited (UAMMCL), a consortium led by the Department of Biotechnology (Government of India) and Punjab, to revolutionize pure-vegetarian animal feed and moringa production. Supported by the State Council for Science Technology. ,

The company has received an export order from Avon Animal Health, Bangladesh to distribute animal health products and educate farmers about their effectiveness.Additionally, the company is working on expanding into the business-to-consumer (B2C) market by appointing more than 100 dealers across India.

It plans to cross 300 distribution touch points and aims to strengthen its market presence and offer innovative products directly to consumers.

In FY24, Ajooni Biotech’s net profit increased by 93.75 per cent to Rs 2.1 crore.

Related Posts

  • Pharma
  • July 24, 2025
  • 239 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 310 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra